Modulation of mitochondrial function and morphology by interaction of Omi/HtrA2 with the mitochondrial fusion factor OPA1

Experimental Cell Research

Volumn 316, Issue 7, 2010, Pages 1213-1224

  Kieper, Nicole ^a   Holmström, Kira M ^a   Ciceri, Dalila ^a   Fiesel, Fabienne C ^a   Wolburg, Hartwig ^b   Ziviani, Elena ^c   Whitworth, Alexander J ^c   Martins, L Miguel ^d   Kahle, Philipp J ^a   Krüger, Rejko ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

Fusion; HtrA2; Mitochondria; Omi; OPA1; Parkinson's disease

Indexed keywords

PROTEIN; PROTEIN OPA1; REACTIVE OXYGEN METABOLITE; SERINE PROTEINASE OMI; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROTECTION; CELL STRESS; CONTROLLED STUDY; CYTOSOL; DEGENERATIVE DISEASE; DROSOPHILA; ELECTRON MICROSCOPY; FIBROBLAST; GENETIC COMPLEMENTATION; HELA CELL; HUMAN; HUMAN CELL; IMAGING; IMMUNOPRECIPITATION; INSECT CELL; KNOCKOUT MOUSE; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN PROTEIN INTERACTION; UPREGULATION;

EID: 77950616071     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.01.005     Document Type: Article

References (37)

1. Vande Walle L., Lamkanfi M., Vandenabeele P. The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ. 2008, 15:453-460.
2. Hegde R., Srinivasula S.M., Zhang Z., Wassell R., Mukattash R., Cilenti L., DuBois G., Lazebnik Y., Zervos A.S., Fernandes-Alnemri T., Alnemri E.S. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J. Biol Chem. 2002, 277:432-438.
3. Martins L.M., Iaccarino I., Tenev T., Gschmeissner S., Totty N.F., Lemoine N.R., Savopoulos J., Gray C.W., Creasy C.L., Dingwall C., Downward J. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J. Biol Chem. 2002, 277:439-444.
4. Verhagen A.M., Silke J., Ekert P.G., Pakusch M., Kaufmann H., Connolly L.M., Day C.L., Tikoo A., Burke R., Wrobel C., Moritz R.L., Simpson R.J., Vaux D.L. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J. Biol Chem. 2002, 277:445-454.
5. Inagaki R., Tagawa K., Qi M.L., Enokido Y., Ito H., Tamura T., Shimizu S., Oyanagi K., Arai N., Kanazawa I., Wanker E.E., Okazawa H. Omi/HtrA2 is relevant to the selective vulnerability of striatal neurons in Huntington's disease. Eur. J. Neurosci. 2008, 28:30-40.
6. Martins L.M., Morrison A., Klupsch K., Fedele V., Moisoi N., Teismann P., Abuin A., Grau E., Geppert M., Livi G.P., Creasy C.L., Martin A., Hargreaves I., Heales S.J., Okada H., Brandner S., Schulz J.B., Mak T., Downward J. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol. Cell. Biol. 2004, 24:9848-9862.
7. Jones J.M., Datta P., Srinivasula S.M., Ji W., Gupta S., Zhang Z., Davies E., Hajnoczky G., Saunders T.L., Van Keuren M.L., Fernandes-Alnemri T., Meisler M.H., Alnemri E.S. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature 2003, 425:721-727.
8. Rathke-Hartlieb S., Schlomann U., Heimann P., Meisler M.H., Jockusch H., Bartsch J.W. Progressive loss of striatal neurons causes motor dysfunction in MND2 mutant mice and is not prevented by Bcl-2. Exp. Neurol. 2002, 175:87-97.
9. Strauss K.M., Martins L.M., Plun-Favreau H., Marx F.P., Kautzmann S., Berg D., Gasser T., Wszolek Z., Muller T., Bornemann A., Wolburg H., Downward J., Riess O., Schulz J.B., Kruger R. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 2005, 14:2099-2111.
10. Bogaerts V., Nuytemans K., Reumers J., Pals P., Engelborghs S., Pickut B., Corsmit E., Peeters K., Schymkowitz J., De Deyn P.P., Cras P., Rousseau F., Theuns J., Van Broeckhoven C. Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease. Hum. Mutat. 2008, 29:832-840.
11. Mandemakers W., Morais V.A., De Strooper B. A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J. Cell Sci. 2007, 120:1707-1716.
12. Van Laar V.S., Berman S.B. Mitochondrial dynamics in Parkinson's disease. Exp. Neurol. 2009, 218:247-256.
13. Lee S., Jeong S.Y., Lim W.C., Kim S., Park Y.Y., Sun X., Youle R.J., Cho H. Mitochondrial fission and fusion mediators, hFis1 and OPA1, modulate cellular senescence. J. Biol. Chem. 2007, 282:22977-22983.
14. Cerveny K.L., Tamura Y., Zhang Z., Jensen R.E., Sesaki H. Regulation of mitochondrial fusion and division. Trends Cell Biol. 2007, 17:563-569.
15. Kijima K., Numakura C., Izumino H., Umetsu K., Nezu A., Shiiki T., Ogawa M., Ishizaki Y., Kitamura T., Shozawa Y., Hayasaka K. Mitochondrial GTPase mitofusin 2 mutation in Charcot-Marie-Tooth neuropathy type 2A. Hum. Genet. 2005, 116:23-27.
16. Delettre C., Lenaers G., Griffoin J.M., Gigarel N., Lorenzo C., Belenguer P., Pelloquin L., Grosgeorge J., Turc-Carel C., Perret E., Astarie-Dequeker C., Lasquellec L., Arnaud B., Ducommun B., Kaplan J., Hamel C.P. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat. Genet. 2000, 26:207-210.
17. Alexander C., Votruba M., Pesch U.E., Thiselton D.L., Mayer S., Moore A., Rodriguez M., Kellner U., Leo-Kottler B., Auburger G., Bhattacharya S.S., Wissinger B. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat. Genet. 2000, 26:211-215.
18. Zanna C., Ghelli A., Porcelli A.M., Karbowski M., Youle R.J., Schimpf S., Wissinger B., Pinti M., Cossarizza A., Vidoni S., Valentino M.L., Rugolo M., Carelli V. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain 2008, 131:352-367.
19. Duvezin-Caubet S., Jagasia R., Wagener J., Hofmann S., Trifunovic A., Hansson A., Chomyn A., Bauer M.F., Attardi G., Larsson N.G., Neupert W., Reichert A.S. Proteolytic processing of OPA1 links mitochondrial dysfunction to alterations in mitochondrial morphology. J. Biol. Chem. 2006, 281:37972-37979.
20. Narendra D., Tanaka A., Suen D.F., Youle R.J. Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy 2009, 5.
21. Exner N., Treske B., Paquet D., Holmstrom K., Schiesling C., Gispert S., Carballo-Carbajal I., Berg D., Hoepken H.H., Gasser T., Kruger R., Winklhofer K.F., Vogel F., Reichert A.S., Auburger G., Kahle P.J., Schmid B., Haass C. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci. 2007, 27:12413-12418.
22. De Vos K.J., Sheetz M.P. Visualization and quantification of mitochondrial dynamics in living animal cells. Methods Cell Biol. 2007, 80:627-682.
23. Mukhopadhyay P., Rajesh M., Yoshihiro K., Hasko G., Pacher P. Simple quantitative detection of mitochondrial superoxide production in live cells. Biochem. Biophys. Res. Commun. 2007, 358:203-208.
24. Moisoi N., Klupsch K., Fedele V., East P., Sharma S., Renton A., Plun-Favreau H., Edwards R.E., Teismann P., Esposti M.D., Morrison A.D., Wood N.W., Downward J., Martins L.M. Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response. Cell Death Differ. 2009, 16:449-464.
25. Plun-Favreau H., Klupsch K., Moisoi N., Gandhi S., Kjaer S., Frith D., Harvey K., Deas E., Harvey R.J., McDonald N., Wood N.W., Martins L.M., Downward J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat. Cell Biol. 2007, 9:1243-1252.
26. Krick S., Shi S., Ju W., Faul C., Tsai S.Y., Mundel P., Bottinger E.P. Mpv17l protects against mitochondrial oxidative stress and apoptosis by activation of Omi/HtrA2 protease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14106-14111.
27. Frezza C., Cipolat S., Martins de Brito O., Micaroni M., Beznoussenko G.V., Rudka T., Bartoli D., Polishuck R.S., Danial N.N., De Strooper B., Scorrano L. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 2006, 126:177-189.
28. Zhang D., Lu C., Whiteman M., Chance B., Armstrong J.S. The mitochondrial permeability transition regulates cytochrome c release for apoptosis during endoplasmic reticulum stress by remodeling the cristae junction. J. Biol. Chem. 2008, 283:3476-3486.
29. Simon-Sanchez J., Singleton A.B. Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum. Mol. Genet. 2008, 17:1988-1993.
30. Ross O.A., Soto A.I., Vilarino-Guell C., Heckman M.G., Diehl N.N., Hulihan M.M., Aasly J.O., Sando S., Gibson J.M., Lynch T., Krygowska-Wajs A., Opala G., Barcikowska M., Czyzewski K., Uitti R.J., Wszolek Z.K., Farrer M.J. Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat. Disord. 2008, 14:539-543.
31. Kawamoto Y., Kobayashi Y., Suzuki Y., Inoue H., Tomimoto H., Akiguchi I., Budka H., Martins L.M., Downward J., Takahashi R. Accumulation of HtrA2/Omi in neuronal and glial inclusions in brains with alpha-synucleinopathies. J. Neuropathol. Exp. Neurol. 2008, 67:984-993.
32. Poole A.C., Thomas R.E., Andrews L.A., McBride H.M., Whitworth A.J., Pallanck L.J. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1638-1643.
33. Whitworth A.J., Lee J.R., Ho V.M., Flick R., Chowdhury R., McQuibban G.A. Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin. Disease Models and Mechanisms 2008, 1:168-174.
34. Tain L.S., Chowdhury R.B., Tao R.N., Plun-Favreau H., Moisoi N., Martins L.M., Downward J., Whitworth A.J., Tapon N. Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK1 independently from Parkin. Cell Death Differ. 2009.
35. Yun J., Cao J.H., Dodson M.W., Clark I.E., Kapahi P., Chowdhury R.B., Guo M. Loss-of-function analysis suggests that Omi/HtrA2 is not an essential component of the PINK1/PARKIN pathway in vivo. J. Neurosci. 2008, 28:14500-14510.
36. Lutz A.K., Exner N., Fett M.E., Schlehe J.S., Kloos K., Lammermann K., Brunner B., Kurz-Drexler A., Vogel F., Reichert A.S., Bouman L., Vogt-Weisenhorn D., Wurst W., Tatzelt J., Haass C., Winklhofer K.F. Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J. Biol. Chem. 2009, 284:22938-22951.
37. Yamaguchi R., Lartigue L., Perkins G., Scott R.T., Dixit A., Kushnareva Y., Kuwana T., Ellisman M.H., Newmeyer D.D. Opa1-mediated cristae opening is Bax/Bak and BH3 dependent, required for apoptosis, and independent of Bak oligomerization. Mol. Cell 2008, 31:557-569.